All In Biotech

Drug Trial Radar · NCT03085810

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,225

Actual

Start

Mar 24, 2017

Primary completion

Apr 27, 2023

Study completion Apr 27, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks. The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • OcrelizumabDrug

    Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)Time frame: Baseline up to 4 years
  2. Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSSTime frame: At Weeks 24 and 48 during Year 1
  3. Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSSTime frame: Year 1 (Weeks 24 and 48)
  4. Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSSTime frame: At Weeks 48, 72 and 96 during Year 2
  5. Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSSTime frame: Year 2 (Weeks 72 and 96)
  6. Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSSTime frame: At Weeks 144, 168 and 192 during Year 4
  7. Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSSTime frame: Year 4 (Weeks 168 and 192)
  8. Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSSTime frame: Year 1 (Week 48)
  9. Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSSTime frame: Year 2 (Week 96)
  10. Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSSTime frame: Year 3
  11. Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSSTime frame: Year 4
  12. Mean Change From Baseline in EDSS Score at Week 24Time frame: From Baseline to Week 24
  13. Mean Change From Baseline in EDSS Score at Week 48Time frame: From Baseline to Week 48
  14. Mean Change From Baseline in EDSS Score at Week 72Time frame: From Baseline to Week 72
  15. Mean Change From Baseline in EDSS Score at Week 96Time frame: Baseline, Week 96
  16. Mean Change From Baseline in EDSS Score at Week 120Time frame: Baseline, Week 120
  17. Mean Change From Baseline in EDSS Score at Week 144Time frame: Baseline, Week 144
  18. Mean Change From Baseline in EDSS Score at Week 168Time frame: Baseline, Week 168
  19. Mean Change From Baseline in EDSS Score at Week 192Time frame: Baseline, Week 192
  20. Percentage of Participants Without Protocol-Defined Event of Disease ActivityTime frame: Baseline up to 4 years
  21. Percentage of Participants Without RelapseTime frame: Baseline up to 4 years
  22. Annualized Relapse RateTime frame: Baseline up to 4 years
  23. Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion SubstudyTime frame: Week 24 through Week 144

Locations

193 sites in 29 countries. Site status is shown where the registry gives one.

  • University of California Irvine

    Irvine, California

  • Palo Alto Medical Foundation Research Center

    Sunnyvale, California

  • University of Colorado Denver

    Aurora, Colorado

  • Advanced Neurology of Colorado, LLC

    Fort Collins, Colorado

  • KI Health Partners, LLC; New England Institute for Clinical Research

    Stamford, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of South Florida - Bradenton

    Tampa, Florida

  • Shepherd Center Inc.

    Atlanta, Georgia

  • College Park Family Care Ctr

    Overland Park, Kansas

  • The NeuroMedical Center

    Baton Rouge, Louisiana

  • Maine Medical Center

    Scarborough, Maine

  • University of Maryland Medical Center; Department of Neurology

    Baltimore, Maryland

  • Neurology Center of New England

    Foxborough, Massachusetts

  • Dragonfly Research, LLC

    Wellesley, Massachusetts

  • Minneapolis Clinic of Neurology

    Golden Valley, Minnesota

  • Cleveland Clinic Lou Ruvo; Center for Brain Research

    Las Vegas, Nevada

  • Columbia University Medical Center

    New York, New York

  • Island Neurological Associates, P.C.

    Plainview, New York

  • Neurology Associates PA

    Hickory, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40

    Cleveland, Ohio

  • Neurology Specialists, Inc

    Dayton, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Kane Hall Barry Neurology

    Bedford, Texas

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington

  • Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders

    Milwaukee, Wisconsin

  • Centro de Especialidades Neurológicas y Rehabilitación - CENyR

    Buenos Aires, Argentina

  • Hospital Churruca Visca

    Buenos Aires, Argentina

  • Fundacion Rosarina de Neurorehabilitacion

    Rosario, Argentina

  • Brain and Mind Centre

    Camperdown, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • John Hunter Hospital

    New Lambton, New South Wales, Australia

  • Royal North Shore Hospital; Department of Neurology

    St Leonards, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Box Hill Hospital; Department of Neurology

    Box Hill, Victoria, Australia

  • Austin Hospital; Department of Neurology

    Heidelberg, Victoria, Australia

  • Royal Melbourne Hospital; Department of Neurology

    Parkville, Victoria, Australia

  • Perron Institute for Neurological and Translational Science

    Nedlands, Western Australia, Australia

  • Medizinische Universität Graz; Universitätsklinik für Neurologie

    Graz, Austria

  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie

    Innsbruck, Austria

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.